Key Highlights
- AC Immune's lead programme, an anti-amyloid active immunotherapy (ACI-24) for Alzheimer's, is partnered with Takeda, which triggered a $12 million milestone in the first half of 2026.
- Its pipeline also includes an anti-tau collaboration with Eli Lilly and an anti-alpha-synuclein immunotherapy for Parkinson's, with data expected in the second half of 2026.
- It held CHF 75.4 million in cash at mid-2026, funding operations into the fourth quarter of 2027.
Brain-disease research matters for AC Immune (NASDAQ:ACIU) because treating neurodegenerative diseases is the company's entire purpose. AC Immune, a Swiss biotechnology company, develops therapies, including active immunotherapies that prompt the body's own immune system to attack disease-causing proteins, aimed at Alzheimer's, Parkinson's, and related conditions.
The shares trade in the Nasdaq Composite, which includes essentially all Nasdaq-listed common equity; for a clinical-stage company, that's membership by listing rather than any selection on size or profitability.
A Partnered Pipeline
AC Immune's approach is distinctive in that much of its pipeline is backed by major partners, which both validates the science and shares the cost. Its lead Alzheimer's programme, ACI-24, is partnered with Takeda, which triggered a $12 million milestone payment in the first half of 2026. Twelve-month interim data from 74 patients showed the therapy to be generally safe and well tolerated, with no evidence of the brain swelling that has troubled some amyloid treatments. Separately, an anti-tau programme is being advanced with Eli Lilly, and an anti-alpha-synuclein immunotherapy for Parkinson's, ACI-7104, is in Phase 2, with results expected in the second half of 2026.
The Finances
AC Immune held CHF 75.4 million in cash at June 30, 2026, funding operations into the fourth quarter of 2027, excluding any further milestone payments. Its net loss for the first half was CHF 12.9 million, much reduced from the prior year, helped by partner payments.
The Opportunity
The opportunity is enormous in principle: effective treatments for Alzheimer's and Parkinson's would address vast unmet need. AC Immune's partnerships with Takeda and Eli Lilly are significant endorsements, bringing funding, expertise, and milestone payments. The safety profile of its lead Alzheimer's immunotherapy is a potential differentiator, and upcoming Parkinson's data offer a near-term catalyst.
The Value of Big-Pharma Backing
Developing a drug through late-stage trials in Alzheimer's or Parkinson's can cost hundreds of millions of dollars, far beyond the means of a company AC Immune's size to fund alone. By partnering its most advanced programmes, AC Immune shares those costs and risks while receiving upfront and milestone payments and eventual royalties.
The flip side is dependence: a partner's strategic priorities can change, and a decision by Takeda or Lilly to slow or drop a programme would remove both funding and validation at a stroke.
Risks
Alzheimer's and Parkinson's have humbled many well-funded programmes, and there's a real chance AC Immune's therapies don't show a convincing clinical benefit despite encouraging early signals. The company is lossmaking and would need more Capital to reach the market. Its reliance on partners means a decision to deprioritize a programme could be damaging. Competition in Alzheimer's and Parkinson's is intense.
Waiting on What the Trials Reveal
The signals that matter are clinical data across the pipeline, especially the second-half-2026 Parkinson's results and continued Alzheimer's data from the Takeda-partnered programme; further milestone payments; the cash position relative to its late-2027 runway; and any new partnerships. AC Immune is pursuing some of the hardest problems in medicine with credible partners and adequate funding, but its story will be written by whether its immunotherapies can translate promising biology into real patient benefit.






Please wait processing your request...